Latest Headlines

Latest Headlines

U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancer

Merck's Keytruda is two-for-two with the U.K.'s cost watchdog, nabbing another thumbs-up to treat skin cancer days after the National Institute of Health and Care Excellence signed off on the med for patients who have already received treatment.

Ruling on Merck diabetes drug shows domestic firms not favored in India courts

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, said this week's decision by the Delhi High Court against homegrown Glenmark Pharmaceuticals showed "due process was followed" and that Indian companies could not count on Indian courts for special treatment, according to a report in the Wall Street Journal.

Merck notches another win in India patent battle over diabetes bestsellers

Everything is coming up roses for Merck in its patent battle with India's Glenmark Pharmaceuticals over copycats of the drugmaker's diabetes meds Januvia and Janumet, as the Delhi High Court barred the generics company from selling cheap knockoff versions of the drugs in the country.

Merck-partnered Euroscreen raises €16M to support IND filing

Euroscreen has topped up its bank balance to support the globalization of its clinical trial program. The €16 million ($18 million) round will allow the G-protein coupled receptor specialist to file an IND and advance ongoing Phase II trials of its lead candidate in women's health diseases.

U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer

Merck's Keytruda got a green light from the U.K.'s cost-effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.

UPDATED: Merck's Keytruda snags FDA approval for NSCLC, but label is narrow

Chalk up another approval for Merck & Co.'s Keytruda. And it's a significant one, as it fights for market share against Bristol-Myers Squibb's Opdivo in the PD-1/PD-L1 field. The FDA Friday gave an accelerated approval for Keytruda for use on advanced non-small cell lung cancer (NSCLC). Opdivo is awaiting an accelerated approval.

Merck adds oncolytics combo study to its huge Keytruda effort

Merck and Houston-based DNAtrix have struck a deal to collaborate on a combination study of the pharma giant's checkpoint inhibitor Keytruda with the biotech's oncolytics immunotherapy DNX-2401.

UPDATED: NewLink wins $26.1M in government funding to advance Ebola vaccine

NewLink Genetics won a total of $26.1 million in funding to further the development of its candidate Ebola vaccine from the DOD's Defense Threat Reduction Agency and HHS' BARDA in the span of just over a week. The company has licensed the research, development and manufacturing of the jab to Merck.

Merck bags Japanese approval for a weekly diabetes drug

Merck, building on the success of its diabetes blockbuster Januvia, won a first global approval for a long-acting form of the drug, convincing Japanese regulators to approve its new weekly product.

One win, one loss in Merck's PhIII double header for C. diff

Merck says that it's ready to apply for EU and U.S. marketing approval for the anti-infective bezlotoxumab, flagging a pivotal clinical success which arrived four years after the pharma giant launched its late-stage program. But the pharma giant also sounded taps for a related Phase III effort on actoxumab.